TNG462
| 中文名称 | TNG462 |
|---|---|
| 中文同义词 | TNG462;N-(6-氨基-5-乙基-3-吡啶基)-2-[(2R,5S)-5-甲基-2-[2-(1-甲基-4-哌啶基)苯并[D]噻唑-5-基]-1-哌啶基]-2-氧代乙酰胺;化合物 TNG-462;(2R,5S)-N-(6-氨基-5-乙基-3-吡啶基)-5-甲基-2-[2-(1-甲基-4-哌啶基)-5-苯并噻唑基]-Α-氧代-1-哌啶乙酰胺;N-(6-氨基-5-乙基吡啶-3-基)-2-((2R,5S)-5-甲基-2-(2-(1-甲基哌啶-4-基)苯并[D]噻唑-5-基)哌啶-1-基)-2-氧代乙酰胺;TNG-462(N-(6-amino-5-ethylpyridin-3-yl)-2-((2R,5S)-5-methyl-2-(2-(1-methylpiperidin-4-yl)benzo[d]thiazol-5-yl)piperidin-1-yl)-2-oxoacetamide);TNG-462(PRMT5 抑制剂) |
| 英文名称 | N-(6-amino-5-ethylpyridin-3-yl)-2-((2R,5S)-5-methyl-2-(2-(1-methylpiperidin-4-yl)benzo[d]thiazol-5-yl)piperidin-1-yl)-2-oxoacetamide |
| 英文同义词 | N-(6-amino-5-ethylpyridin-3-yl)-2-((2R,5S)-5-methyl-2-(2-(1-methylpiperidin-4-yl)benzo[d]thiazol-5-yl)piperidin-1-yl)-2-oxoacetamide;N-(6-Amino-5-ethyl-3-pyridyl)-2-[(2R,5S)-5-methyl-2-[2-(1-methyl-4-piperidyl)benzo[d]thiazol-5-yl]-1-piperidyl]-2-oxoacetamide;(2R,5S)-N-(6-Amino-5-ethyl-3-pyridinyl)-5-methyl-2-[2-(1-methyl-4-piperidinyl)-5-benzothiazolyl]-α-oxo-1-piperidineacetamide;1-Piperidineacetamide, N-(6-amino-5-ethyl-3-pyridinyl)-5-methyl-2-[2-(1-methyl-4-piperidinyl)-5-benzothiazolyl]-α-oxo-, (2R,5S)-;N-(6-amino-5-ethyl-3-pyridyl)-2-[(2R,5S)-5-methyl-2-[2-(1-methyl-4-piperidyl)-1,3-benzothiazol-5-yl]-1-piperidyl]-2-oxo-acetamide;vopimetostat |
| CAS号 | 2760483-96-1 |
| 分子式 | C28H36N6O2S |
| 分子量 | 520.69 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 2760483-96-1.mol |
| 结构式 |  |
TNG462 性质
| 密度 | 1.266±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) |
|---|---|
| 形态 | 固体 |
| 酸度系数(pKa) | 11.337±0.70(predicted) |
| 颜色 | 白色至米白色 |
| InChIKey | DHAGMIPSRSPWSH-GAJHUEQPSA-N |
| SMILES | C(N1C[C@H](CC[C@@H]1C1=CC=C2SC(C3CCN(CC3)C)=NC2=C1)C)(=O)C(=O)NC1=CN=C(C(=C1)CC)N |
TNG-462 是一种口服有效的选择性 PRMT5 抑制剂，对甲基硫腺苷磷酸化酶 (MTAP) 缺失和/或甲硫腺苷 (MTA) 累积型癌症具有抗肿瘤活性。